Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus

Journal of Rheumatology

Volumn 38, Issue 4, 2011, Pages 780-781

  Giannitti, Chiara ^a   Sebastiani, Gian Domenico ^b   Manganelli, Stefania ^a   Galeazzi, Mauro ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; ANTIVIRUS AGENT; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; HEPATITIS B SURFACE ANTIGEN; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS DNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; TREATMENT RESPONSE; VIRUS ACTIVATION; VIRUS CARRIER;

ADULT; AGED; ANTIBODIES; CARRIER STATE; DRUG TOXICITY; FEMALE; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 79953312839     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101157     Document Type: Letter

References (10)

1. Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-α blocker in the treatment of rheumatic diseases. J Rheumatol 2010;37:346-50.
2. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9. (Pubitemid 44133258)
3. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004;11:18-25.
4. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9. (Pubitemid 46668261)
5. Montiel PM, Solis JA, Chirinos JA, Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-20. (Pubitemid 351541107)
6. Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology 2007;46:1381. (Pubitemid 47244524)
7. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5.
8. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179.
9. Jansen TL. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers? Arthritis Res Ther 2010;12:103.
10. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, et al. Safety of tumor necrosis factor-α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 2010;62:749-54.